ClinicalTrials.gg

Program

Flurbiprofen

Also written as “flurbiprofen”, “Flurbiprofen tablet” and “Flurbiprofen 100 mg”.

Its studies are mostly in Pharyngitis · HIV Infections · Diabetes Mellitus, Type 2 · Anemia · Periodontitis, led by 7 companies.

Furthest: phase 3, since Mar 1, 200712 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline40 open or runningphase 1since Mar 1, 2007Mar 1, 2007none ahead
Reckitt30 open or runningphase 3since Jan 13, 2010Jan 13, 2010none ahead
Bristol-Myers Squibb10 open or runningphase 1since Aug 26, 2014Aug 26, 2014none ahead
Dexcel Pharma Technologies10 open or runningphase 2since Dec 27, 2009Dec 27, 2009none ahead
Idorsia Pharmaceuticals10 open or runningphase 1since Feb 15, 2022Feb 15, 2022none ahead
Institut de Recherches Internationales Servier (I.R.I.S.)10 open or runningphase 1since Nov 14, 2025Nov 14, 2025none ahead
Teikoku Seiyaku10 open or runningphase 1since Jan 19, 2025Jan 19, 2025none ahead

Also a collaborator on its studies: socrametrics-gmbh and hwi-pharma-services-gmbh.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2007First study: phase 1 study in AnemiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT00443170 · 90 enrolled · Australia
  2. Feb 1, 2008Phase 1 study in Diabetes Mellitus, Type 2GlaxoSmithKline · NCT00615212 · 23 enrolled · United States
  3. Jul 23, 2009Phase 1 study in Drug InteractionsGlaxoSmithKline · NCT00964106 · 87 enrolled · Korea, Republic of
  4. Dec 27, 2009Dexcel Pharma Technologies's first study: phase 2 study in PeriodontitisNew to Dexcel Pharma TechnologiesDexcel Pharma Technologies · NCT01040286 · Israel
  5. Jan 13, 2010Reckitt's first studies: 2 phase 3 studies in PharyngitisNew to ReckittReckitt · NCT01049334, NCT01048866
  6. Oct 22, 2013Phase 3 study in PharyngitisReckitt · NCT01986361 · 122 enrolled · United States
  7. Aug 26, 2014Bristol-Myers Squibb's first study: phase 1 study in Drug-drug Interaction StudyNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02227173 · 20 enrolled · United States
  8. Jun 5, 2020Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT04425902 · 20 enrolled · United States
  9. Feb 15, 2022Idorsia Pharmaceuticals's first study: phase 1 study in HealthyNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT05254548 · 22 enrolled · Germany
  10. Jan 19, 2025Teikoku Seiyaku's first study: phase 1 study in HealthyNew to Teikoku SeiyakuTeikoku Seiyaku · NCT06823284 · 26 enrolled · Germany
  11. Nov 14, 2025Institut de Recherches Internationales Servier (I.R.I.S.)'s first study: phase 1 study in Healthy Adult ParticipantsNew to Institut de Recherches Internationales Servier (I.R.I.S.)Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07235748 · 28 enrolled · United Kingdom

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07235748Healthy Adult Participants · United Kingdom1CompletedInstitut de Recherches Internationales Servier (I.R.I.S.)Dec 23, 202528
NCT06823284Healthy · Germany1CompletedTeikoku SeiyakuFeb 12, 202526
NCT05254548Healthy · Germany1CompletedIdorsia PharmaceuticalsApr 13, 202222
NCT04425902HIV Infections · United States1CompletedGlaxoSmithKlineMar 10, 202120
NCT02227173Drug-drug Interaction Study · United States1CompletedBristol-Myers SquibbNov 201420
NCT01986361Pharyngitis · United States3CompletedReckittApr 2014122
NCT01049334Pharyngitis · United States3CompletedReckittMar 2011204
NCT01048866Pharyngitis · United States3CompletedReckittMar 2011198
NCT01040286Periodontitis · Israel2CompletedDexcel Pharma Technologies
NCT00964106Drug Interactions · Korea, Republic of1CompletedGlaxoSmithKlineAug 29, 201187
NCT00615212Diabetes Mellitus, Type 2 · United States1CompletedGlaxoSmithKlineFeb 15, 200823
NCT00443170Anemia · Australia1CompletedGlaxoSmithKline90

How it is read

Names in the registry

  • “Flurbiprofen”, 7 entries
  • “flurbiprofen”, 2 entries
  • “Flurbiprofen tablet”, 1 entry
  • “Flurbiprofen 100 mg”, 1 entry
  • “omeprazole, caffeine, flurbiprofen, rosiglitazone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.